[Acute Acalculous Cholecystitis Associated with Sunitinib Treatment for Renal Cell Carcinoma].
Se Woong ChoiJeong Min LeeDong Gyun KimMyung Hwan NohPublished in: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi (2021)
A 64-year-old man was treated with sunitinib as a first-line therapy for metastatic renal cell carcinoma. He was given oral sunitinib in cycles of 50 mg once daily for 2 weeks followed by a week off. During the 5th week of treatment right upper quadrant pain developed, but this resolved spontaneously during the 6th week (off treatment). However, on the 8th week of treatment, he was admitted to hospital because the acute right upper quadrant pain recurred with nausea, vomiting, and fever. Acute acalculous cholecystitis was then diagnosed by ultrasonography and CT. In addition, his laboratory findings indicated disseminated intravascular coagulation. Accordingly, sunitinib therapy was discontinued and broad-spectrum antibiotics initiated. He subsequently recovered after emergent percutaneous cholecystostomy. His Naranjo Adverse Drug Reaction Probability Scale score was 7, indicaing a probable association of the event with sunitinib. Suspicion of sunitinib-related acute cholecystitis is required, because, although uncommon, it can be life-threatening.
Keyphrases
- metastatic renal cell carcinoma
- renal cell carcinoma
- liver failure
- adverse drug
- respiratory failure
- drug induced
- magnetic resonance imaging
- chronic pain
- healthcare
- computed tomography
- emergency department
- randomized controlled trial
- physical activity
- pain management
- stem cells
- magnetic resonance
- coronary artery
- aortic dissection
- combination therapy
- minimally invasive
- intensive care unit
- replacement therapy
- cell therapy
- acute respiratory distress syndrome
- pet ct
- abdominal pain